Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

antibody/PNE-based biologic agent ABBV-461

A biologic agent composed of an antibody fragment targeting an as of yet unidentified tumor-associated antigen (TAA) that is linked to a 14 aa peptide epitope, or alpha-peptide neo-epitope (PNE), recognizable by autologous alpha-PNE switchable CAR-T cells CLBR001, that may be used to activate CLBR001. Upon administration of the antibody-based biologic agent ABBV-461, and upon co-administration of CLBR001, the antibody moiety targets and binds to tumor cells expressing the TAA. In turn, the PNE part of ABBV-461 binds to the binding domain of CLBR001, thereby activating CLBR001. This induces selective toxicity in and causes lysis of the TAA-expressing tumor cells to which ABBV-461 is bound.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TAA antibody fragment/PNE biologic molecule ABBV-461
switch biologic molecule ABBV-461
TAA-specific CLBR001 adapter molecule ABBV-461
Code name:ABBV 461
ABBV-461
ABBV461
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search